Literature DB >> 9815975

PAX5 expression correlates with increasing malignancy in human astrocytomas.

E T Stuart1, C Kioussi, A Aguzzi, P Gruss.   

Abstract

Rearrangements concerning chromosome 9p are a late event in the progression of human astrocytic tumors to their most malignant form. The expression of PAX5, which maps to chromosome 9p13, was studied in primary human brain tumors of astrocytic origin. Whereas murine Pax5 is not expressed in the forebrain at any stage, PAX5 expression was increased in a range of astrocytomas (WHO grades II-IV) which originated in the forebrain. Expression of PAX5 was limited to those cells which also expressed the oncogenes myc, fos, or jun singularly or in combination. The epidermal growth factor receptor was highly expressed in glioblastoma multiform tumors in areas which were also highly PAX5 positive. We conclude that the missappropriate expression of PAX5 may aid in promoting the progression of astrocytomal malignancy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 9815975

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  15 in total

1.  Transcriptional regulation of co-expressed microRNA target genes.

Authors:  Ying Wang; Xiaoman Li; Haiyan Hu
Journal:  Genomics       Date:  2011-10-02       Impact factor: 5.736

2.  Deregulation of PAX-5 by translocation of the Emu enhancer of the IgH locus adjacent to two alternative PAX-5 promoters in a diffuse large-cell lymphoma.

Authors:  M Busslinger; N Klix; P Pfeffer; P G Graninger; Z Kozmik
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

3.  Pax-5 immunoexpression in various types of benign and malignant tumours: a high-throughput tissue microarray analysis.

Authors:  Paulette Mhawech-Fauceglia; Rhakee Saxena; Shaozeng Zhang; Luigi Terracciano; Guido Sauter; Arundhuti Chadhuri; Francois R Herrmann; Remedios Penetrante
Journal:  J Clin Pathol       Date:  2006-07-12       Impact factor: 3.411

4.  Co-Localization and Interaction of Pax5 with Iba1 in Brain of Mice.

Authors:  Shashank Kumar Maurya; Rajnikant Mishra
Journal:  Cell Mol Neurobiol       Date:  2017-11-13       Impact factor: 5.046

5.  Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins.

Authors:  M Bernasconi; A Remppis; W J Fredericks; F J Rauscher; B W Schäfer
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-12       Impact factor: 11.205

6.  B cell activator PAX5 promotes lymphomagenesis through stimulation of B cell receptor signaling.

Authors:  Diana Cozma; Duonan Yu; Suchita Hodawadekar; Anna Azvolinsky; Shannon Grande; John W Tobias; Michele H Metzgar; Jennifer Paterson; Jan Erikson; Teresa Marafioti; John G Monroe; Michael L Atchison; Andrei Thomas-Tikhonenko
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

7.  The expression of PAX5, p53 immunohistochemistry and p53 mutation analysis in superficial bladder carcinoma tissue. Correlation with pathological findings and clinical outcome.

Authors:  M Babjuk; V Soukup; J Mares; J Dusková; Z Sedlácek; M Trková; L Pecen; J Dvorácek; T Hanus; R Kocvara; J Novák; C Povýsil
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

8.  Expression of mRNA for a newly identified Pax5 exon is reduced in multiple myeloma.

Authors:  Nancy D Borson; Martha Q Lacy; Peter J Wettstein
Journal:  Mamm Genome       Date:  2006-03-03       Impact factor: 2.957

9.  Loss of p53 function through PAX-mediated transcriptional repression.

Authors:  E T Stuart; R Haffner; M Oren; P Gruss
Journal:  EMBO J       Date:  1995-11-15       Impact factor: 11.598

10.  Neuroblastoma and pre-B lymphoma cells share expression of key transcription factors but display tissue restricted target gene expression.

Authors:  Anna Lagergren; Christina Manetopoulos; Håkan Axelson; Mikael Sigvardsson
Journal:  BMC Cancer       Date:  2004-11-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.